ClinicalTrials.gg
CompletedNCT00409838Updated Aug 8, 2013Results posted

A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
34th of 63
113 · median 119
Started
2007
with 5 others
Phase 3
26 of 63
2 open now
Registered
14th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 14th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the clinical efficacy of abatacept (body-weight tiered dose approximating 10 mg/kg) compared with placebo on a background of methotrexate after 6 months (Day 169) of treatment in Korean patients with active rheumatoid arthritis and an inadequate clinical response to methotrexate

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis, with inadequate response to methotrexate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Rheumatoid arthritis (RA) for longer than 1 year from the time of the initial diagnosis of RA
  • Patients must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg, and a stable dose for 28 days prior to treatment (Day 1)
  • Methotrexate weekly dose as low as 10 mg is permitted for patients who cannot tolerate higher doses

Key Exclusion Criteria:

  • Evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrollment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Abatacept and Methotrexate

    Drug: Abatacept · Drug: Methotrexate

  • Placebo comparator
    Placebo and Methotrexate

    (standard of care)

    Drug: Methotrexate · Drug: Placebo

  • Experimental
    Abatacept - Open Label

    Open-label extension phase

    Drug: Abatacept · Drug: Methotrexate

Interventions

  • Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months

    Also known as: Orencia, BMS-188667

  • Tablets, Oral, ≥ 15 mg, weekly, 6 months

  • DrugPlacebo

    IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months

  • Solution, intravenous, 10 mg/kg, every 28 days

    Also known as: Orencia, BMS-188667

  • Tablets, oral, 15 mg weekly to be adjusted according to patient condition

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)

    The ACR 20 is based on 20% improvement (compared with baseline values) in tender and swollen joint counts and on 20% improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.

    Time frame: At Day 169

  2. Long-term Extension (LTE) (Open-Label) Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuatons Due to SAEs, Adverse Events (AEs), Related AEs, and Discontinuations Due to AEs

    AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

    Time frame: Day 169 to up to 56 days post the last dose (Day 1485) in the LTE period

Secondary outcomes

  1. Percentage of Participants With American College of Rheumatology (ACR) ACR50 and ACR70 Response at Day 169

    The ACR defines ACR 50 and ACR70 response as a 50% or 70% improvement (compared with baseline values) in tender and swollen joint counts and 50% or 70% improvement in 3 of the remaining 5 core set measures (patient global assessment of pain, patient global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and 1 acute phase reactant value (C-reactive protein).

    Time frame: At Day 169

  2. Percentage of Participants With at Least 20%, 50%, or 70% Improvement From Baseline in American College of Rheumatology (ACR) Core Components

    The ACR defines improvement in core components as 20%, 50%, or 70% improvement in tender and swollen joint counts and 3 of the remaining core components: patient global assessment of disease activity, physician global assessment of disease activity, patient assessment of pain, patient self-assessed disability (Health Assessment Questionnaire Disability Index \[HAQ-DI\]), and levels of 1 acute phase reactant (C-reactive protein levels or erythrocyte sedimentation rate.) The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning; scale=0 (no disability) to 3 (completely disabled); total possible score=24. The higher the score, the greater the disability.

    Time frame: From Baseline to Day 169

  3. Change From Baseline in Disease Activity Scores (DAS) Based on C-reactive Protein (DAS 28 [CRP]) Levels or Erythrocyte Sedimentation Rate (DAS 28[ESR])

    Adjusted mean change from baseline. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission). CRP or ESR give estimations of DAS28 values on a group level. Change from Baseline=Postbaseline - Baseline value.

    Time frame: From Baseline to Days 169 and 1485

  4. Change From Baseline to Day 169 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

    Adjusted mean change from baseline. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.

    Time frame: From Baseline to Day 169

  5. Change From Baseline to Day 169 in Analysis of Short-Form 36 (SF-36) Health Survey Questionnaire Domains

    Adjusted mean change from baseline. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life and comprised of 8 domains( including 4 physical and 4 mental subscales) used to derive the physical and mental component summary scores. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Change from baseline=postbaseline - baseline value.

    Time frame: From Baseline to Day 169

  6. Percentage of Participants Experiencing Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), Related SAEs and AEs, and Discontinuations Due to SAEs and AEs During the Double-Blind Period

    AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

    Time frame: Throughout double-blind study period (up to Day 169); table includes data up to 56 days past double-blind period or start of the open-label period, whichever occurred first.

  7. Abatacept Pharmacokinetic (PK) Parameters: Time to Maximum Concentration (Tmax) and Half-Life of Elimination (T-Half)

    Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Tmax = the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. T-Half = the biological half-life or elimination half life of a substance is the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity.

    Time frame: At the end of infusion and 2 to 4 hours after the start of infusion on Day 85, at anytime between Day 92 and 96, and pre-dose on Day 113

  8. Abatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax)

    Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Maximum Concentration (Cmax)= the maximum plasma concentration of the drug.

    Time frame: At the end of infusion and 2 to 4 hours after the start of the infusion on Day 85, at anytime between Day 92 and 96, and pre-dose on Day 113

  9. Abatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC)

    Area Under the Plasma Concentration-Time Curve (AUC), a measure of drug absorption, in a dosing interval of 28 days from Day 85 to Day 113. Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.

    Time frame: At the end of infusion, 2 to 4 hours after the start of infusion on Day 85, anytime between Day 92 and 96, and predose on Day 113

  10. Abatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT)

    Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Clearance is a pharmacokinetic parameter that describes how quickly drugs are eliminated, metabolized or distributed throughout the body.

    Time frame: Day 29, every 28 days until Day 141

  11. Abatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS)

    The volume of distribution of drug at steady state (VSS). Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.

    Time frame: At the end of infusion, 2 to 4 hours after the start of infusion on Day 85, anytime between Day 92 and 96, and predose on Day 113

  12. Summary Statistics of Minimum Observed Serum Concentration (Cmin) for Abatacept

    Minimum concentration (Cmin) of Abatacept 500 mg and 750 mg at given time points

    Time frame: At the end of infusion and 2 to 4 hours after the start of the infusion on Day 85

  13. Immunogenicity of Abatacept- Number of Participants With Reactivity Toward CTLA4-IG and CTLA4-T at Day 169

    Immunogenicity was determined by measuring adult subject sera for reactivity against the whole Abatacept molecule (CTLA4Ig) and CTLA4-T (CTLA4 without the Ig regions).

    Time frame: Day 169

  14. Change From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169

    Mean change in surrogate marker mean ESR. A surrogate marker is an indirect measurement of effectiveness. Change from Baseline = postbaseline - baseline value.

    Time frame: From Baseline to Day 169

  15. Change From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169

    Mean change in RF. A surrogate marker is an indirect measurement of effectiveness. Mean change from Baseline = postbaseline - baseline value.

    Time frame: Baseline, Day 169

  16. LTE Period: Overall Number of Participants With Positive Results of Immunogenicity Samples

    Positive antibody titers were identified by validated enzyme-linked immunosorbent assay results. On-treatment samples were obtained during the LTE period, and posttreatment samples were following the last infusion of study medication.

    Time frame: Days 169, at 6-month intervals on-treatment, and at Days 28, 56, and 85 after the last infusion of study medication in the LTE period

  17. Percentage of Participants Achieving ACR20, ACR50, and ACR70 Over Time

    The ACR 20, ACR50, and ACR70 are based on 20%, 50% and 70% improvement, respectively, (compared with baseline values) in tender and swollen joint counts and on 20%, 50% and 70%, respectively, improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.

    Time frame: Days 15 through 1569

  18. Percentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI)

    Improvement is measured by an improved response of at least 0.3 units from baseline on the HAQ-DI score. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.

    Time frame: At Day 1485

  19. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

    The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.

    Time frame: Day 1485

  20. Changes From Baseline in Short-Form 36 (SF-36) Physical and Mental Health Summaries

    The SF-36 is a 36-item questionnaire used to measure Quality of Life over 8 physically and emotionally based areas: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Answers to each question correspond to a precoded numeric value. An aggregate percentage score is reached for each of the 8 sections and is based on answers to questions. The mean average is worked out for each section. Scores range from 0% (lowest level of functioning) to 100% (highest level of functioning, with higher score indicated increasing levels of functioning.

    Time frame: At Day 1485

  21. Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and With EULAR-defined Remission

    EULAR defines LDAS as a disease activity score as measured by c-reactive protein (DAS28-CRP) ≤3.2 and remission as DAS28-CRP \<2.6

    Time frame: At Days 169 and 1485

  22. Changes From Baseline in the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) Scores

    The SDAI is the sum of 5 parameters: Tender joint (TJC) and swollen joint(SJC)counts, based on a 28-joint assessment; patient global (PtGA)and physician global assessments (PGA), assessed on 0-10 cm visual analog scale (VAS), on which higher scores=greater affection due to disease activity DA); and C-reactive protein level. SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low DA, \>11 to 26=moderate DA, and \>26=high DA. SJC is assessed at each visit, with no swelling=0, swelling=1. TJC is assessed through identification of joints painful under pressure or to passive motion at each visit, with no tenderness=0, tenderness=1. Higher score=greater affection due to DA. CDAI is sum of 4 parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score=0-76. CDAI \<=2.8 indicates disease remission, \>2.8 to 10=low DA, \>10 to 22=moderate DA, and \>22=high DA.

    Time frame: At Days 169 and 1569

  23. Percentage of Participants With Low Disease Activity Score (LDAS) or Who Are in Remission

    LDAS is defined as a Disease Activity Score C-reactive protein (DAS28-CRP) level \<=3.2. Remission is defined as a DAS28-CRP level \<2.6.

    Time frame: At Days 169, 337, 729, 1149, and 1485

  24. Change From Baseline in Levels of C-reactive Protein (CRP)

    Time frame: Days 169 to 1569

  25. Change From Baseline in Erythrocyte Sedimentation Rate

    Time frame: Days 169 to 1569

07

Results

Posted Jan 26, 2010

Participant flow

Short-term Period
Participant flow — Short-term Period
MilestoneAbatacept, 10 mg/kgPlacebo
Started5657
Treated (baseline) population5557
Completed5352
Not completed35
Withdrew: Adverse event01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject23
Withdrew: Never treated10
Long-term Extension Period
Participant flow — Long-term Extension Period
MilestoneAbatacept, 10 mg/kgPlacebo
Started1050
Completed870
Not completed180
Withdrew: Adverse event100
Withdrew: Death10
Withdrew: Lack of efficacy20
Withdrew: Withdrawal by subject30
Withdrew: Poor compliance/noncompliance10
Withdrew: Pregnancy10

Outcome measures

PrimaryPercentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)

The ACR 20 is based on 20% improvement (compared with baseline values) in tender and swollen joint counts and on 20% improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.

Time frame:
At Day 169
Reported as:
Number · percentage of participants
Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)
percentage of participantsAbatacept, 10 mg/kgPlacebo
Percentage of Participants Meeting the Criteria of the American College of Rheumatology for 20% Improvement (ACR20)65.542.1
SecondaryPercentage of Participants With American College of Rheumatology (ACR) ACR50 and ACR70 Response at Day 169

The ACR defines ACR 50 and ACR70 response as a 50% or 70% improvement (compared with baseline values) in tender and swollen joint counts and 50% or 70% improvement in 3 of the remaining 5 core set measures (patient global assessment of pain, patient global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and 1 acute phase reactant value (C-reactive protein).

Time frame:
At Day 169
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) ACR50 and ACR70 Response at Day 169
Percentage of participantsAbataceptPlacebo
ACR 5032.715.8
ACR 7014.57.0
SecondaryPercentage of Participants With at Least 20%, 50%, or 70% Improvement From Baseline in American College of Rheumatology (ACR) Core Components

The ACR defines improvement in core components as 20%, 50%, or 70% improvement in tender and swollen joint counts and 3 of the remaining core components: patient global assessment of disease activity, physician global assessment of disease activity, patient assessment of pain, patient self-assessed disability (Health Assessment Questionnaire Disability Index \[HAQ-DI\]), and levels of 1 acute phase reactant (C-reactive protein levels or erythrocyte sedimentation rate.) The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning; scale=0 (no disability) to 3 (completely disabled); total possible score=24. The higher the score, the greater the disability.

Time frame:
From Baseline to Day 169
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 20%, 50%, or 70% Improvement From Baseline in American College of Rheumatology (ACR) Core Components
Percentage of participantsAbataceptPlacebo
Tender Joints ≥ 20% improvement81.176.9
Tender Joints ≥ 50% improvement66.050.0
Tender Joints ≥ 70% improvement49.123.1
Swollen Joints ≥ 20% improvement92.576.9
Swollen Joints ≥ 50% improvement77.457.7
Swollen Joints ≥ 70% improvement60.440.4
Patient Pain Assessment ≥ 20% improvement73.653.9
Patient Pain Assessment ≥ 50% improvement47.223.1
Patient Pain Assessment ≥ 70% improvement28.311.5
HAQ-DI ≥ 20% improvement67.944.2
HAQ-DI ≥ 50% improvement32.123.1
HAQ-DI ≥ 70% improvement20.85.8
Patient Global Assessment ≥ 20% improvement66.053.9
Patient Global Assessment ≥ 50% improvement39.621.2
Patient Global Assessment ≥ 70% improvement26.411.5
Physician Global Assessment ≥ 20% improvement86.871.2
Physician Global Assessment ≥ 50% improvement60.440.4
Physician Global Assessment ≥ 70% improvement30.219.2
C-reactive Protein ≥ 20% improvement83.061.5
C-reactive Protein ≥ 50% improvement75.553.9
C-reactive Protein ≥ 70% improvement64.228.9
SecondaryChange From Baseline in Disease Activity Scores (DAS) Based on C-reactive Protein (DAS 28 [CRP]) Levels or Erythrocyte Sedimentation Rate (DAS 28[ESR])

Adjusted mean change from baseline. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission). CRP or ESR give estimations of DAS28 values on a group level. Change from Baseline=Postbaseline - Baseline value.

Time frame:
From Baseline to Days 169 and 1485
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity Scores (DAS) Based on C-reactive Protein (DAS 28 [CRP]) Levels or Erythrocyte Sedimentation Rate (DAS 28[ESR])
Units on a scaleAbataceptPlacebo
Day 169: DAS28 (CRP)-2.12 ± 0.17-1.21 ± 0.17
Day 169: DAS28 (ESR)-2.22 ± 0.17-1.15 ± 0.16
Day 1485: DAS28 (CRP) (n=31, 35)-2.97 ± 0.23-3.13 ± 0.22
Day 1485: DAS28 (ESR) (NA)NA ± NANA ± NA
SecondaryChange From Baseline to Day 169 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

Adjusted mean change from baseline. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.

Time frame:
From Baseline to Day 169
Reported as:
Mean · Units on a scale
Change From Baseline to Day 169 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
Units on a scaleAbataceptPlacebo
HAQ Disability Index-0.53 ± 0.07-0.24 ± 0.07
Dressing and Grooming-0.58 ± 0.09-0.37 ± 0.09
Arising-0.58 ± 0.10-0.36 ± 0.10
Eating-0.52 ± 0.09-0.13 ± 0.09
Walking-0.54 ± 0.10-0.23 ± 0.10
Hygiene-0.37 ± 0.09-0.21 ± 0.09
Reaching-0.34 ± 0.11-0.11 ± 0.10
Gripping-0.67 ± 0.11-0.36 ± 0.11
Activities-0.56 ± 0.10-0.25 ± 0.10
SecondaryChange From Baseline to Day 169 in Analysis of Short-Form 36 (SF-36) Health Survey Questionnaire Domains

Adjusted mean change from baseline. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life and comprised of 8 domains( including 4 physical and 4 mental subscales) used to derive the physical and mental component summary scores. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Change from baseline=postbaseline - baseline value.

Time frame:
From Baseline to Day 169
Reported as:
Mean · Units on a scale
Change From Baseline to Day 169 in Analysis of Short-Form 36 (SF-36) Health Survey Questionnaire Domains
Units on a scaleAbataceptPlacebo
Physical Component Summary6.52 ± 1.052.16 ± 1.06
Mental Component Summary8.18 ± 1.374.36 ± 1.38
SecondaryPercentage of Participants Experiencing Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), Related SAEs and AEs, and Discontinuations Due to SAEs and AEs During the Double-Blind Period

AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

Time frame:
Throughout double-blind study period (up to Day 169); table includes data up to 56 days past double-blind period or start of the open-label period, whichever occurred first.
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), Related SAEs and AEs, and Discontinuations Due to SAEs and AEs During the Double-Blind Period
Percentage of participantsAbataceptPlacebo
Deaths01.8
SAEs3.65.3
Related SAEs01.8
Discontinued due to SAEs01.8
AEs70.970.2
Related AEs12.715.8
Discontinued due to AEs01.8
SecondaryAbatacept Pharmacokinetic (PK) Parameters: Time to Maximum Concentration (Tmax) and Half-Life of Elimination (T-Half)

Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Tmax = the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination. T-Half = the biological half-life or elimination half life of a substance is the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity.

Time frame:
At the end of infusion and 2 to 4 hours after the start of infusion on Day 85, at anytime between Day 92 and 96, and pre-dose on Day 113
Reported as:
Mean · Hours
Abatacept Pharmacokinetic (PK) Parameters: Time to Maximum Concentration (Tmax) and Half-Life of Elimination (T-Half)
HoursAbatacept 500 mgAbatacept 750 mgAbatacept 500 mg and 750 mg
Tmax1.385 ± 1.06071.193 ± 0.99561.325 ± 1.0351
T-Half183.583 ± 35.2606172.451 ± 28.7270180.078 ± 33.4795
SecondaryAbatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax)

Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Maximum Concentration (Cmax)= the maximum plasma concentration of the drug.

Time frame:
At the end of infusion and 2 to 4 hours after the start of the infusion on Day 85, at anytime between Day 92 and 96, and pre-dose on Day 113
Reported as:
Mean · μg/mL
Abatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax)
μg/mLAbatacept 500 mgAbatacept 750 mgAbatacept 500 mg and 750 mg
Abatacept Pharmacokinetic (PK) Parameters - Maximum Concentration (Cmax)241.972 ± 41.7191312.591 ± 63.3026264.204 ± 59.0589
SecondaryAbatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC)

Area Under the Plasma Concentration-Time Curve (AUC), a measure of drug absorption, in a dosing interval of 28 days from Day 85 to Day 113. Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.

Time frame:
At the end of infusion, 2 to 4 hours after the start of infusion on Day 85, anytime between Day 92 and 96, and predose on Day 113
Reported as:
Mean · μg.h/mL
Abatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC)
μg.h/mLAbatacept 500 mgAbatacept 750 mgAbatacept 500 mg and 750 mg
Abatacept Pharmacokinetic (PK) Parameters - Area Under the Curve (AUC)38940.063 ± 9731.056148283.479 ± 10283.257241881.508 ± 10743.8152
SecondaryAbatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT)

Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg. Clearance is a pharmacokinetic parameter that describes how quickly drugs are eliminated, metabolized or distributed throughout the body.

Time frame:
Day 29, every 28 days until Day 141
Reported as:
Mean · mL/h/kg
Abatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT)
mL/h/kgAbatacept 500 mgAbatacept 750 mgAbatacept 500 mg and 750 mg
Abatacept Pharmacokinetic (PK) Parameters: Total Body Clearance (CLT)0.269 ± 0.07300.240 ± 0.04600.260 ± 0.0666
SecondaryAbatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS)

The volume of distribution of drug at steady state (VSS). Steady-state PK parameters following administration of body-weight tiered doses approximating 10 mg/kg.

Time frame:
At the end of infusion, 2 to 4 hours after the start of infusion on Day 85, anytime between Day 92 and 96, and predose on Day 113
Reported as:
Mean · L/kg
Abatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS)
L/kgAbatacept 500 mgAbatacept 750 mgAbatacept 500 mg and 750 mg
Abatacept Pharmacokinetic (PK) Parameters: Volume at Steady State (VSS)0.064 ± 0.01650.055 ± 0.01420.061 ± 0.0162
SecondarySummary Statistics of Minimum Observed Serum Concentration (Cmin) for Abatacept

Minimum concentration (Cmin) of Abatacept 500 mg and 750 mg at given time points

Time frame:
At the end of infusion and 2 to 4 hours after the start of the infusion on Day 85
Reported as:
Mean · μg/mL
Summary Statistics of Minimum Observed Serum Concentration (Cmin) for Abatacept
μg/mLAbatacept 500 mgAbatacept 750 mgAbatacept 500 mg and 750 mg
Day 2937.76 ± 10.97152.19 ± 19.61942.30 ± 15.611
Day 5719.96 ± 11.33724.42 ± 7.69721.31 ± 10.504
Day 8517.45 ± 7.44220.83 ± 10.74918.52 ± 8.661
Day 11317.51 ± 6.85822.06 ± 9.36518.94 ± 7.936
SecondaryImmunogenicity of Abatacept- Number of Participants With Reactivity Toward CTLA4-IG and CTLA4-T at Day 169

Immunogenicity was determined by measuring adult subject sera for reactivity against the whole Abatacept molecule (CTLA4Ig) and CTLA4-T (CTLA4 without the Ig regions).

Time frame:
Day 169
Reported as:
Number · participants
Immunogenicity of Abatacept- Number of Participants With Reactivity Toward CTLA4-IG and CTLA4-T at Day 169
participantsAbatacept + Background Methotrexate
Reactivity toward CTLA4-T0
Reactivity toward CTLA4Ig0
SecondaryChange From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169

Mean change in surrogate marker mean ESR. A surrogate marker is an indirect measurement of effectiveness. Change from Baseline = postbaseline - baseline value.

Time frame:
From Baseline to Day 169
Reported as:
Mean · mm/h
Change From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169
mm/hAbataceptPlacebo
Change From Baseline in Surrogate Marker Erythrocyte Sedimentation Rate (ESR) at Day 169-30.0 ± 2.86-4.44 ± 3.87
SecondaryChange From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169

Mean change in RF. A surrogate marker is an indirect measurement of effectiveness. Mean change from Baseline = postbaseline - baseline value.

Time frame:
Baseline, Day 169
Reported as:
Mean · IU/mL
Change From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169
IU/mLAbataceptPlacebo
Change From Baseline in Surrogate Marker Rheumatoid Factor (RF) at Day 169-54.1 ± 20.52-12.1 ± 14.38
PrimaryLong-term Extension (LTE) (Open-Label) Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuatons Due to SAEs, Adverse Events (AEs), Related AEs, and Discontinuations Due to AEs

AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

Time frame:
Day 169 to up to 56 days post the last dose (Day 1485) in the LTE period
Reported as:
Number · Participants
Long-term Extension (LTE) (Open-Label) Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuatons Due to SAEs, Adverse Events (AEs), Related AEs, and Discontinuations Due to AEs
ParticipantsAll Treated
Deaths1
SAEs41
Related SAEs10
Discontinuations due to SAEs8
AEs100
Related AEs45
Discontinuations due to AEs10
SecondaryLTE Period: Overall Number of Participants With Positive Results of Immunogenicity Samples

Positive antibody titers were identified by validated enzyme-linked immunosorbent assay results. On-treatment samples were obtained during the LTE period, and posttreatment samples were following the last infusion of study medication.

Time frame:
Days 169, at 6-month intervals on-treatment, and at Days 28, 56, and 85 after the last infusion of study medication in the LTE period
Reported as:
Number · Participants
LTE Period: Overall Number of Participants With Positive Results of Immunogenicity Samples
ParticipantsAll Treated
Overall14
On-treatment9
Posttreatment11
SecondaryPercentage of Participants Achieving ACR20, ACR50, and ACR70 Over Time

The ACR 20, ACR50, and ACR70 are based on 20%, 50% and 70% improvement, respectively, (compared with baseline values) in tender and swollen joint counts and on 20%, 50% and 70%, respectively, improvement in 3 of the remaining 5 core set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function) and 1 acute phase reactant value.

Time frame:
Days 15 through 1569
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR20, ACR50, and ACR70 Over Time
Percentage of participantsAbatacept, 10 mg/kgPlacebo
Day 15 ACR2013.2 (4.1 to 22.3)11.5 (2.9 to 20.2)
Day 15 ACR501.9 (0.0 to 10.1)3.8 (0.5 to 13.2)
Day 15 ACR700 (NA to NA)0 (NA to NA)
Day 29 ACR2024.5 (12.9 to 36.1)21.2 (10.1 to 32.3)
Day 29 ACR501.9 (0.0 to 10.0)7.7 (2.1 to 18.5)
Day 29 ACR701.9 (0.0 to 10.0)3.8 (0.5 to 13.2)
Day 57 ACR20 (n=52, 52)51.9 (38.3 to 65.5)23.1 (11.6 to 34.5)
Day 57 ACR50 (n=52, 52)5.8 (1.2 to 15.9)7.7 (2.1 to 18.5)
Day 57 ACR70 (n=52, 52)1.9 (0.0 to 10.3)5.8 (1.2 to 15.9)
Day 85 ACR2058.5 (45.2 to 71.8)36.5 (23.5 to 49.6)
Day 85 ACR5017.0 (6.9 to 27.1)9.6 (1.6 to 17.6)
Day 85 ACR705.7 (1.2 to 15.7)7.7 (2.1 to 18.5)
Day 113 ACR2064.2 (51.2 to 77.1)48.1 (34.5 to 61.7)
Day 113 ACR5030.2 (17.8 to 42.5)11.5 (2.9 to 20.2)
Day 113 ACR703.8 (0.5 to 13.0)7.7 (2.1 to 18.5)
Day 141 ACR2066.0 (53.3 to 78.8)53.8 (40.3 to 67.4)
Day 141 ACR5030.2 (17.8 to 42.5)11.5 (2.9 to 20.2)
Day 141 ACR7015.1 (5.5 to 24.7)7.7 (2.1 to 18.5)
Day 169 ACR2067.9 (55.4 to 80.5)46.2 (32.6 to 59.7)
Day 169 ACR5034.0 (21.2 to 46.7)17.3 (7.0 to 27.6)
Day 169 ACR7015.1 (5.5 to 24.7)7.7 (2.1 to 18.5)
Day 197 ACR20 (n=53, 50)75.5 (63.9 to 87.1)60.0 (46.4 to 73.6)
Day 197 ACR50 (n=53, 51)45.3 (31.9 to 58.7)37.3 (24.0 to 50.5)
Day 197 ACR70 (n=53, 51)22.6 (11.4 to 33.9)11.8 (2.9 to 20.6)
Day 225 ACR2075.5 (63.9 to 87.1)65.4 (52.5 to 78.3)
Day 225 ACR5049.1 (35.6 to 62.5)32.7 (19.9 to 45.4)
Day 225 ACR7022.6 (11.4 to 83.9)13.5 (4.2 to 22.7)
Day 253 ACR20 (n=52, 51)71.2 (58.8 to 83.5)64.7 (51.6 to 77.8)
Day 253 ACR50 (n=52, 51)44.2 (30.7 to 57.7)35.3 (22.2 to 48.4)
Day 253 ACR70 (n=52, 51)21.2 (10.1 to 32.3)13.7 (4.3 to 23.2)
Day 337 ACR20 (n=52, 51)78.8 (67.7 to 89.9)62.7 (49.5 to 76.0)
Day 337 ACR50 (n=52, 51)48.1 (34.5 to 61.7)43.1 (29.5 to 56.7)
Day 337 ACR70 (n=52, 51)30.8 (18.2 to 43.3)17.6 (7.2 to 28.1)
Day 421 ACR20 (n=51, 51)84.3 (74.3 to 94.3)78.4 (67.1 to 89.7)
Day 421 ACR50 (n=51, 51)49.0 (35.3 to 62.7)56.9 (43.3 to 70.5)
Day 421 ACR70 (n=51, 51)29.4 (16.9 to 41.9)31.4 (18.6 to 44.1)
Day 505 ACR20 (n=50, 51)88.0 (79.0 to 97.0)84.3 (74.3 to 94.3)
Day 505 ACR50 (n=50, 51)62.0 (48.5 to 75.5)56.9 (43.3 to 70.5)
Day 505 ACR70 (n=50, 51)40.0 (26.4 to 53.6)25.5 (13.5 to 37.5)
Day 561 ACR20 (n=50, 50)88.0 (79.0 to 97.0)86.0 (76.4 to 95.6)
Day 561 ACR50 (n=50, 50)64.0 (50.7 to 77.3)60.0 (46.4 to 73.6)
Day 561 ACR70 (n=50, 50)38.0 (24.5 to 51.5)32.0 (19.1 to 44.9)
Day 645 ACR20 (n=50, 50)86.0 (76.4 to 95.6)82.0 (71.4 to 92.6)
Day 645 ACR50 (n=50, 50)54.0 (40.2 to 67.8)56.0 (42.2 to 69.8)
Day 645 ACR70 (n=50, 50)38.0 (24.5 to 51.5)34.0 (20.9 to 47.1)
Day 729 ACR20 (n=49, 50)83.7 (73.3 to 94.0)74.0 (61.8 to 86.2)
Day 729 ACR50 (n=49, 50)63.3 (49.8 to 76.8)54.0 (40.2 to 67.8)
Day 729 ACR70 (n=49, 50)34.7 (21.4 to 48.0)32.0 (19.1 to 44.9)
Day 813 ACR20 (n=48, 49)91.7 (83.8 to 99.5)79.6 (68.3 to 90.9)
Day 813 ACR50 (n=48, 49)58.3 (44.4 to 72.3)59.2 (45.4 to 72.9)
Day 813 ACR70 (n=48, 49)41.7 (27.7 to 55.6)34.7 (21.4 to 48.0)
Day 897 ACR20 (n=46, 49)80.4 (69.0 to 91.9)79.6 (68.3 to 90.9)
Day 897 ACR50 (n=46, 49)56.5 (42.2 to 70.8)53.1 (39.1 to 67.0)
Day 897 ACR70 (n=46, 49)39.1 (25.0 to 53.2)34.7 (21.4 to 48.0)
Day 981 ACR20 (n=44, 48)84.1 (73.3 to 94.9)79.2 (67.7 to 90.7)
Day 981 ACR50 (n=44, 48)61.4 (47.0 to 75.8)60.4 (46.6 to 74.3)
Day 981 ACR70 (n=43, 48)34.9 (20.6 to 49.1)41.7 (27.7 to 55.6)
Day 1065 ACR20 (n=45, 48)80.0 (68.3 to 91.7)79.2 (67.7 to 90.7)
Day 1065 ACR50 (n=45, 48)64.4 (50.5 to 78.4)60.4 (46.6 to 74.3)
Day 1065 ACR70 (n=45, 48)42.2 (27.8 to 56.7)43.8 (29.7 to 57.8)
Day 1149 ACR20 (n=45, 48)84.4 (73.9 to 95.0)75.0 (62.8 to 87.2)
Day 1149 ACR50 (n=45, 48)55.6 (41.0 to 70.1)62.5 (48.8 to 76.2)
Day 1149 ACR70 (n=45, 48)35.6 (21.6 to 49.5)43.8 (29.7 to 57.8)
Day1233 ACR20 (n=44, 48)84.1 (73.3 to 94.9)79.2 (67.7 to 90.7)
Day1233 ACR50 (n=44, 48)63.6 (49.4 to 77.9)52.1 (38.0 to 66.2)
Day1233 ACR70 (n=44, 48)43.2 (28.5 to 57.8)41.7 (27.7 to 55.6)
Day 1317 ACR20 (n=44, 47)90.9 (82.4 to 99.4)76.6 (64.5 to 88.7)
Day 1317 ACR50 (n=44, 47)63.6 (49.4 to 77.9)53.2 (38.9 to 67.5)
Day 1317 ACR70 (n=44, 47)40.9 (26.4 to 55.4)36.2 (22.4 to 49.9)
Day 1401 ACR20 (n=41, 43)90.2 (81.2 to 99.3)81.4 (69.8 to 93.0)
Day 1401 ACR50 (n=41, 43)68.3 (54.0 to 82.5)51.2 (36.2 to 66.1)
Day 1401 ACR70 (n=41, 43)39.0 (24.1 to 54.0)39.5 (24.9 to 54.1)
Day 1485 ACR20 (n=31, 35)83.9 (70.9 to 96.8)85.7 (74.1 to 97.3)
Day 1485 ACR50 (n=31, 35)67.7 (51.3 to 84.2)62.9 (46.8 to 78.9)
Day 1485 ACR70 (n=31, 35)38.7 (21.6 to 55.9)45.7 (29.2 to 62.2)
Day 1569 ACR20 (n=20, 18)100.0 (100.0 to 100.0)88.9 (74.4 to 100.0)
Day 1569 ACR50 (n=20, 18)80.0 (62.5 to 97.5)72.2 (51.5 to 92.9)
Day 1569 ACR70 (n=20, 18)30.0 (9.9 to 50.1)44.4 (21.5 to 67.4)
SecondaryPercentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI)

Improvement is measured by an improved response of at least 0.3 units from baseline on the HAQ-DI score. The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.

Time frame:
At Day 1485
Reported as:
Number · Percentage of participants
Percentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI)
Percentage of participantsAbatacept, 10 mg/kgPlacebo
Percentage of Participants With Physical Function Response as Assessed Using the Health Assessment Questionnaire Disability Index (HAQ-DI)77.460.0
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

The HAQ-DI assesses a patient's level of functional ability via 20 questions in 8 categories of functioning. Patients respond on a scale from 0 (no disability) to 3 (completely disabled); total possible score=24. Higher score indicates greater disability. Change from baseline= postbaseline - baseline value.

Time frame:
Day 1485
Reported as:
Mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
Units on a scaleAbatacept, 10 mg/kgPlacebo
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score-0.76 ± 0.14-0.53 ± 0.11
SecondaryChanges From Baseline in Short-Form 36 (SF-36) Physical and Mental Health Summaries

The SF-36 is a 36-item questionnaire used to measure Quality of Life over 8 physically and emotionally based areas: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Answers to each question correspond to a precoded numeric value. An aggregate percentage score is reached for each of the 8 sections and is based on answers to questions. The mean average is worked out for each section. Scores range from 0% (lowest level of functioning) to 100% (highest level of functioning, with higher score indicated increasing levels of functioning.

Time frame:
At Day 1485
Reported as:
Mean · Units on a scale
Changes From Baseline in Short-Form 36 (SF-36) Physical and Mental Health Summaries
Units on a scaleAbatacept, 10 mg/kgPlacebo
Physical component score10.34 ± 1.808.48 ± 1.57
Mental component score7.93 ± 2.447.73 ± 2.34
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and With EULAR-defined Remission

EULAR defines LDAS as a disease activity score as measured by c-reactive protein (DAS28-CRP) ≤3.2 and remission as DAS28-CRP \<2.6

Time frame:
At Days 169 and 1485
Reported as:
Number · Percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and With EULAR-defined Remission
Percentage of participantsAbatacept, 10 mg/kgPlacebo
EULAR-defined LDAS (Day 169)35.813.5
EULAR-defined LDAS (Day 1485) (n=31, 35)61.368.6
EULAR-defined remission (Day 169)24.59.6
EULAR-defined remission(Day 1485) (n=31, 35)35.554.3
SecondaryChanges From Baseline in the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) Scores

The SDAI is the sum of 5 parameters: Tender joint (TJC) and swollen joint(SJC)counts, based on a 28-joint assessment; patient global (PtGA)and physician global assessments (PGA), assessed on 0-10 cm visual analog scale (VAS), on which higher scores=greater affection due to disease activity DA); and C-reactive protein level. SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low DA, \>11 to 26=moderate DA, and \>26=high DA. SJC is assessed at each visit, with no swelling=0, swelling=1. TJC is assessed through identification of joints painful under pressure or to passive motion at each visit, with no tenderness=0, tenderness=1. Higher score=greater affection due to DA. CDAI is sum of 4 parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score=0-76. CDAI \<=2.8 indicates disease remission, \>2.8 to 10=low DA, \>10 to 22=moderate DA, and \>22=high DA.

Time frame:
At Days 169 and 1569
Reported as:
Mean · Units on a scale
Changes From Baseline in the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) Scores
Units on a scaleAbatacept, 10 mg/kgPlacebo
SDAI score (Day 169)-22.84 (-26.58 to -19.0)-14.07 (-17.28 to -10.87)
SDAI score (Day 1569) (n=20, 18)-29.74 (-34.06 to -25.43)-29.20 (-33.70 to -24.70)
CDAI score (Day 169)-20.99 (-24.52 to -17.46)-13.49 (-16.42 to -10.56)
CDAI score (Day 1569) (n=20, 18)-27.79 (-31.78 to -23.80)-27.34 (-31.54 to -23.15)
SecondaryPercentage of Participants With Low Disease Activity Score (LDAS) or Who Are in Remission

LDAS is defined as a Disease Activity Score C-reactive protein (DAS28-CRP) level \<=3.2. Remission is defined as a DAS28-CRP level \<2.6.

Time frame:
At Days 169, 337, 729, 1149, and 1485
Reported as:
Number · Percentage of participants
Percentage of Participants With Low Disease Activity Score (LDAS) or Who Are in Remission
Percentage of participantsAbatacept, 10 mg/kgPlacebo
LDAS (Day 169)35.8 (22.9 to 48.8)13.5 (4.2 to 22.7)
LDAS (Day 337) (n=52, 51)51.9 (38.3 to 65.5)35.3 (22.2 to 48.4)
LDAS (Day 729) (n=48, 50)62.5 (48.8 to 76.2)56.0 (42.2 to 69.8)
LDAS (Day 1149) (n=44,48)63.6 (49.4 to 77.9)60.4 (46.6 to 74.3)
LDAS (Day 1485) (n=31, 35)61.3 (44.1 to 78.4)68.6 (53.2 to 84.0)
Remission (Day 169)24.5 (12.9 to 36.1)9.6 (1.6 to 17.6)
Remission (Day 337) (n=52, 51)34.6 (21.7 to 47.5)23.5 (11.9 to 35.2)
Remission (Day 729) (n=48, 50)43.8 (29.7 to 57.8)38.0 (24.5 to 51.5)
Remission (Day 1149) (n=44,8)38.6 (24.2 to 53.0)50.0 (35.9 to 64.1)
Remission (Day 1485) (n=31, 35)35.5 (18.6 to 52.3)54.3 (37.8 to 70.8)
SecondaryChange From Baseline in Levels of C-reactive Protein (CRP)
Time frame:
Days 169 to 1569
Reported as:
Mean · mg/dL
Change From Baseline in Levels of C-reactive Protein (CRP)
mg/dLAbatacept, 10 mg/kgPlacebo
Day 169-1.85 ± 0.29-0.58 ± 0.34
Day 197 (n=53, 49)-1.87 ± 0.28-1.23 ± 0.36
Day 225-1.73 ± 0.51-1.62 ± 0.32
Day 253 (n=52, 51)-1.91 ± 0.31-1.52 ± 0.32
Day 337 (n=52, 51)-1.94 ± 0.30-1.67 ± 0.32
Day 421 (n=51, 51)-2.06 ± 0.26-1.77 ± 0.33
Day 505 (n=50, 51)-2.10 ± 0.28-1.75 ± 0.33
Day 561 (n=50, 50)-2.23 ± 0.27-1.68 ± 0.39
Day 645 (n=50, 50)-2.24 ± 0.28-1.88 ± 0.34
Day 729 (n=49, 50)-2.29 ± 0.28-1.63 ± 0.37
Day 813 (n=48, 49)-2.24 ± 0.29-1.81 ± 0.34
Day 897 (n=46, 49)-2.41 ± 0.30-1.76 ± 0.35
Day 981 (n=44, 48)-1.99 ± 0.33-1.99 ± 0.36
Day 1065 (n=45, 48)-2.06 ± 0.32-1.47 ± 0.40
Day 1149 (n=45, 48)-2.00 ± 0.34-1.86 ± 0.36
Day 1233 (n=44, 48)-1.96 ± 0.331.70 ± 0.37
Day 1317 (n=44, 47)-2.00 ± 0.35-1.81 ± 0.40
Day 1401 (n=41, 43)-1.93 ± 0.33-1.83 ± 0.40
Day 1485 (n=31, 35)-1.95 ± 0.47-1.86 ± 0.41
Day 1569 (n=20, 18)-2.43 ± 0.43-1.68 ± 0.42
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate
Time frame:
Days 169 to 1569
Reported as:
Mean · mm/h
Change From Baseline in Erythrocyte Sedimentation Rate
mm/hAbatacept, 10 mg/kgPlacebo
Day 169-30.60 ± 2.93-7.12 ± 3.84
Day 197 (n=53, 49)-28.43 ± 3.27-15.14 ± 3.79
Day 225-27.30 ± 3.09-20.27 ± 3.51
Day 253 (n=52, 51)-27.85 ± 3.24-20.78 ± 3.97
Day 337 (n=52, 51)-28.58 ± 3.35-23.86 ± 3.78
Day 421 (n=51, 51)-28.45 ± 3.34-24.94 ± 3.86
Day 505 (n=50, 51)-31.30 ± 3.46-24.69 ± 4.07
Day 561 (n=50, 49)-29.32 ± 3.63-24.90 ± 4.24
Day 645 (n=50, 50)-28.22 ± 3.74-27.38 ± 4.10
Day 729 (n=49, 50)-32.80 ± 3.70-23.04 ± 3.60
Day 813 (n=48, 47)-31.52 ± 3.95-22.91 ± 4.03
Day 897 (n=46, 49)-34.37 ± 4.13-18.22 ± 4.65
Day 981 (n=44, 48)-33.61 ± 3.68-21.54 ± 4.53
Day 1065 (n=45, 47)-31.53 ± 3.95-22.09 ± 4.37
Day 1149 (n=45, 48)-31.00 ± 4.59-20.29 ± 4.61
Day 1233 (n=42, 48)-30.93 ± 5.08-22.10 ± 4.70
Day 1317 (n=43, 47)-33.67 ± 4.45-21.89 ± 4.48
Day 1401 (n=41, 43)-32.41 ± 4.83-23.88 ± 4.91
Day 1485 (n=31, 35)-33.81 ± 6.96-25.69 ± 5.70
Day 1569 (n=20, 18)-46.80 ± 6.79-23.33 ± 5.85

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept 10 mg/kg—2/55 (3.6%)27/55 (49.1%)
Placebo—3/57 (5.3%)26/57 (45.6%)
Most frequent serious events
Most frequent serious events
EventAbatacept 10 mg/kgPlacebo
ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications1/550/57
LUMBAR SPINAL STENOSISMusculoskeletal and connective tissue disorders1/550/57
ADRENAL CYSTEndocrine disorders0/551/57
SEPSISInfections and infestations0/551/57
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders0/551/57
PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders0/551/57
INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders0/551/57
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAbatacept 10 mg/kgPlacebo
NASOPHARYNGITISInfections and infestations4/559/57
COUGHRespiratory, thoracic and mediastinal disorders6/553/57
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations5/556/57
WEIGHT INCREASEDInvestigations4/550/57
HEADACHENervous system disorders3/553/57
DYSPEPSIAGastrointestinal disorders3/552/57
MOUTH ULCERATIONGastrointestinal disorders3/551/57
EPIGASTRIC DISCOMFORTGastrointestinal disorders3/551/57
BACK PAINMusculoskeletal and connective tissue disorders3/552/57
PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders3/550/57

Baseline characteristics

Age Continuous
Age Continuous(years)AbataceptPlaceboTotal
Mean47.2 ± 12.249.9 ± 10.648.6 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptPlaceboTotal
Female474996
Male8816
weight
weight(kilograms)AbataceptPlaceboTotal
Mean56.5 ± 9.554.2 ± 7.555.3 ± 8.6
08

Study locations

7 sites
  • Local Institution
    Seoul, Sungdong-Gu 133-792, Korea, Republic of
  • Local Institution
    Anyang, 431-070, Korea, Republic of
  • Local Institution
    Daegu, 705-718, Korea, Republic of
  • Local Institution
    Daejeon, 302-799, Korea, Republic of
  • Local Institution
    Seoul, 110-744, Korea, Republic of
  • Local Institution
    Seoul, 137-040, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Jul 2008 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2006
First posted
Dec 11, 2006
Start
Apr 2007
Primary completionActual
Jul 2008
CompletionActual
Dec 2011
Results first posted
Jan 26, 2010
Last update
Aug 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00409838
Responsible party
Sponsor
First posted
Dec 11, 2006
Start date
Apr 2007
Primary completion
Jul 2008
Completion
Dec 2011
Results posted
Jan 26, 2010
Last update
Aug 8, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion